1. TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY. (12th June 2019) Authors: Kim, Y.H.; Ortiz‐Romero, P.L.; Pro, B.; Sokol, L.; Scarisbrick, J.; Musiek, A.; Vermeer, M.; Dummer, R.; Halwani, A.; Fierro, M.; Moriya, J.; Leoni, M.; Bagot, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T‐CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Witzig, T.; Sokol, L.; Kim, W.; Foss, F.; Jacobsen, E.; de la Cruz Vincente, F.; Caballero, D.; Advani, R.; Roncero Vidal, J.M.; Marin‐Niebla, A.; Rodriguez Izquierdo, A.; de Ona Navarrete, R.; Terol, M.J.; Domingo‐Domenech, E.; Rodriguez, M.; Piris, M.A.; Bolognese, J.; Janes, M.R.; Burrows, F.;... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Falchi, L.; Lue, J.K.; Montanari, F.; Marchi, E.; Amengual, J.E.; Sawas, A.; Deng, C.; Khan, K.; Kim, H.A.; Rada, A.; Malanga, M.; Francescone, M.F.; Soderquist, C.R.; Park, D.C.; Bhagat, G.; Sokol, L.; Shustov, A.R.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MULTI‐CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC‐486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T‐CELL LYMPHOMA. (12th June 2019) Authors: Ruan, J.; Leonard, J.P.; Coleman, M.; Rutherford, S.; Van Besien, K.; Rodriguez, A.; Benderoff, L.; Mehta‐Shah, N.; Moskowitz, A.; Sokol, L.; Cerchietti, L.; Inghirami, G.; Martin, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. (20th August 2021) Authors: Cowan, R.A.; Scarisbrick, J.J.; Zinzani, P.L.; Nicolay, J.P.; Sokol, L.; Pinter‐Brown, L.; Quaglino, P.; Iversen, L.; Dummer, R.; Musiek, A.; Foss, F.; Ito, T.; Rosen, J‐P.; Medley, M.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 11(2021) Page Start: 2225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN-EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT. (23rd June 2022) Authors: Zhang, Y.; Nguyen, L.; Lu, C.; Wang, E.; Lauw, M.; Ball, S.; Dong, N.; Moscinski, L.; Chan, O.; Yun, S.; Sallman, D.; Sokol, L.; Shah, B.; Lancet, J.; Komrokji, R.; Kuykendall, A.; Padron, E.; Zhang, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES. (April 2015) Authors: Basiorka, A.; Mcgraw, K.; Eksioglu, E.; Chen, X.; Johnson, J.; Padron, E.; Komrokji, R.; Sokol, L.; Coll, R.; O'Neill, L.; Cooper, M.; Robertson, A.; Wei, S.; List, A. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. (June 2017) Authors: Witzig, T.; Sokol, L.; Jacobsen, E.; Advani, R.; Mondejar, R.; Piris, M.; Burrows, F.; Melvin, C.; Mishra, V.; Scholz, C.; Gualberto, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗